AGFS AgroFresh Solutions Inc

Copies to:

SCHEDULE 13D

This Amendment No. 3 to Schedule 13D (“Amendment No. 3”) amends and supplements the Schedule 13D, filed by The Dow Chemical Company (“Dow”) on August 10, 2015, as amended by Amendment No. 1 to Schedule 13D (“Amendment No. 1”), filed by Dow on May 12, 2016, and as amended by Amendment No. 2 to Schedule 13D (“Amendment No. 2”), filed by Dow on April 12, 2017 relating to the Common Stock of the Issuer (as so amended through Amendment No. 2, the “Schedule 13D”). Unless otherwise indicated, all capitalized terms in this Amendment No. 3 have the meanings set forth for such terms in the Schedule 13D. This Amendment No. 3 amends and supplements the Schedule 13D to include the information set forth below. Except as specifically provided herein, this Amendment No. 3 does not modify any of the information previously reported in the Schedule 13D.

Item 2 of the Schedule 13D is hereby amended and restated in its entirety as follows:

This Schedule 13D is being filed by (i) DowDuPont Inc. (“DowDuPont”), a Delaware corporation, with a co-principal business and office address of c/o The Dow Chemical Company, 2030 Dow Center, Midland, MI 48674 and c/o E. I. du Pont de Nemours and Company, 974 Centre Road, Wilmington, DE 19805 and (ii) Dow, a Delaware corporation, with a principal business and office address of 2030 Dow Center, Midland, MI 48674 (each of Dow and DowDuPont, a “Reporting Person” and, collectively, the “Reporting Persons”).

The name, residence or business address, present principal occupation or employment (including the name and the principal business address, if other than the Reporting Person, of any corporation or other organization in which such employment is conducted) of the directors and executive officers of each Reporting Person (each, a “Scheduled Person” and, collectively, the “Scheduled Persons”) are as set forth on Appendix A attached hereto and are incorporated herein by reference. Except as set forth otherwise on Appendix A, each person identified on Appendix A is a citizen of the United States.

DowDuPont is a holding company comprised of Dow and E. I. du Pont de Nemours and Company (“DuPont”) with the intent to form strong, independent, publicly traded companies in agriculture, materials science and specialty products sectors that will lead their respective industries through productive, science-based innovation to meet the needs of customers and help solve global challenges.

During the last five years, none of the Reporting Persons, nor, to the best of their knowledge, any of the Scheduled Persons, has been (i) convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

This Amendment No. 3 is being filed while the Reporting Persons have obtained certain information from their respective directors and executive officers.

The Reporting Persons have entered into a Joint Filing Agreement, dated as of September 8, 2017, a copy of which is attached as Exhibit 8 hereto, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) of the Securities Exchange Act.

Item 3 of the Schedule 13D is hereby amended and supplemented by adding the following paragraphs at the end thereof:

Effective at 11:59 p.m. on August 31, 2017 (the “Effective Time”), the Reporting Persons completed the merger of equals transaction contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 (the “Merger Agreement”), by and among Dow, DuPont, DowDuPont, Diamond Merger Sub, Inc. (“Diamond Merger

Sub”) and Orion Merger Sub, Inc. (“Orion Merger Sub”). Pursuant to the Merger Agreement, at the Effective Time, (i) Diamond Merger Sub was merged with and into Dow, with Dow surviving the merger as a wholly owned subsidiary of DowDuPont (the “Diamond Merger”) and (ii) Orion Merger Sub was merged with and into DuPont, with DuPont surviving the merger as a subsidiary of DowDuPont (the “Orion Merger” and, together with the Diamond Merger, the “Mergers”). Upon the consummation of the Mergers, each of Dow and DuPont became a subsidiary of DowDuPont. As a result of the Diamond Merger, DowDuPont acquired beneficial ownership of the shares of Common Stock of the Issuer that are beneficially owned by Dow and reflected in the Schedule 13D.

The description of the Merger Agreement and the transactions contemplated thereby contained in this Amendment No. 3 does not purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the Merger Agreement, a copy of which is filed as Exhibits 2.1 and 2.2 to DowDuPont’s Current Report on Form 8-K, filed with the SEC on September 1, 2017.

The Reporting Persons are filing this Amendment No. 3 with respect to the beneficial ownership of shares of Common Stock acquired by DowDuPont in connection with the consummation of the Mergers.

Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following paragraphs at the end thereof:

The information included in Item 3 of Amendment No. 3 is incorporated herein by reference.

Except as set forth in Item 6 of the Schedule 13D (as amended by this Amendment No. 3), none of the Reporting Persons has any present plan or proposal that relates to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D. However, the Reporting Persons reserve the right to adopt such plans or proposals in the future.

Item 5. Interest in Securities of the Issuer

Item 5(a) – (b) and Item 5(c) are hereby amended and restated in its entirety with the following:

(a) – (b)    As of the date hereof, the Reporting Persons beneficially own 17,710,393 shares of Common Stock, representing 35.2% of the Issuer’s outstanding Common Stock, and 3,000,000 warrants to purchase Common Stock, each to purchase one share of Common Stock. If the Reporting Persons were to exercise the warrants to purchase Common Stock and no other person exercised warrants to purchase Common Stock held by that person, the Reporting Persons would beneficially own 20,710,393 shares of Common Stock, representing 41.1% of the Issuer’s outstanding Common Stock. The percentage set forth in this Item 5 is based on 50,337,705 outstanding shares of Common Stock as of August 4, 2017, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, filed with the SEC on August 9, 2017. To the best of the Reporting Persons’ knowledge, none of the Scheduled Persons beneficially own any shares of Common Stock.

The Reporting Persons each have indirect beneficial ownership of the 20,710,393 shares of Common Stock, which Common Stock is directly owned by Rohm and Haas Company, a wholly owned subsidiary of Dow (“R&H”).

(c)    During the past 60 days, Dow acquired beneficial ownership of 39,857 shares of the Issuer’s Common Stock through acquisitions made between August 15, 2017 and August 30, 2017 on the open market on account of R&H at prices ranging from $6.95 per share to $7.00 per share (exclusive of any fees, commissions or other expenses). DowDuPont acquired beneficial ownership of such shares on August 31, 2017 upon consummation of the Mergers. Upon request, the Reporting Persons hereby undertake to provide to the Issuer, any stockholder of the Issuer, or the Staff of the SEC, full information regarding the number of shares of the Issuer’s Common Stock purchased and the prices of each trade within the ranges set forth in this Item 5(c).

Except as described in this Amendment No. 3, none of the Reporting Persons has effected any transactions in shares of Common Stock of the Issuer during the past 60 days. To the knowledge of the Reporting Persons, there have been no transactions by any of the Scheduled Persons in shares of Common Stock of the Issuer during the past 60 days.

Item 6 of the Schedule 13D is hereby amended and supplemented by adding the following paragraph at the end thereof:

The information contained in Item 3 of Amendment No. 3 is incorporated herein by reference. The rights of DowDuPont with respect to the shares of Common Stock are also subject to the terms and conditions of the Investor Rights Agreement, the Warrant Purchase Agreement, the Board Representation Letter Agreement, the Lock-Up Extension Agreement, the Letter Agreement, the Stock Buyback Agreement and the Termination of Warrant Purchase Agreement.

Item 7 of the Schedule 13D is hereby amended and supplemented by adding the following additional exhibit:

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated as September 8, 2017

DOWDUPONT INC.

THE DOW CHEMICAL COMPANY

APPENDIX A

Information Concerning Executive Officers and

Directors of DowDuPont Inc.

The current executive officers and directors of DowDuPont Inc. and their respective business addresses and present principal occupation or employment (and the name, principal business and address of any such employment, if not with one of the Reporting Persons) are listed below. Unless otherwise indicated, all positions of the executive officers set forth below opposite an individual’s name refer to positions with DowDuPont Inc. In addition, unless otherwise indicated, all individuals identified below are citizens of the United States of America.

Information Concerning Executive Officers and

Directors of The Dow Chemical Company

The current executive officers and directors of The Dow Chemical Company and their respective business addresses and present principal occupation or employment (and the name, principal business and address of any such employment, if not with one of the Reporting Persons) are listed below. Unless otherwise indicated, all positions set forth below opposite an individual’s name refer to positions within The Dow Chemical Company and each individual is a citizen of the United States of America. In addition, unless otherwise indicated, the business address for each individual is c/o The Dow Chemical Company, 2030 Dow Center, Midland, Michigan 48674.

EXHIBIT INDEX